233 related articles for article (PubMed ID: 30253794)
1. Response to PD1 inhibition in conventional chondrosarcoma.
Wagner MJ; Ricciotti RW; Mantilla J; Loggers ET; Pollack SM; Cranmer LD
J Immunother Cancer; 2018 Sep; 6(1):94. PubMed ID: 30253794
[TBL] [Abstract][Full Text] [Related]
2. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse.
Zheng B; Ren T; Huang Y; Sun K; Wang S; Bao X; Liu K; Guo W
J Hematol Oncol; 2018 Feb; 11(1):16. PubMed ID: 29409495
[TBL] [Abstract][Full Text] [Related]
3. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
4. Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab.
Roth P; Valavanis A; Weller M
Neuro Oncol; 2017 Mar; 19(3):454-456. PubMed ID: 28039369
[No Abstract] [Full Text] [Related]
5. Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy.
Lattanzi M; Deng FM; Chiriboga LA; Femia AN; Meehan SA; Iyer G; Voss MH; Sundatova Y; Huang WC; Balar AV
J Immunother Cancer; 2018 Oct; 6(1):97. PubMed ID: 30285856
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
Sagiv O; Thakar SD; Kandl TJ; Ford J; Sniegowski MC; Hwu WJ; Esmaeli B
JAMA Ophthalmol; 2018 Nov; 136(11):1236-1241. PubMed ID: 30352118
[TBL] [Abstract][Full Text] [Related]
7. Complete Response of a Patient With Metastatic Sarcomatoid Renal Cell Carcinoma to a Programmed Death-1 Checkpoint Inhibitor.
El Mouallem N; Smith SC; Paul AK
J Oncol Pract; 2018 Aug; 14(8):511-513. PubMed ID: 29920137
[No Abstract] [Full Text] [Related]
8. Nivolumab and its use in the second-line treatment of metastatic urothelial cancer.
Raggi D; Necchi A; Giannatempo P
Future Oncol; 2018 Nov; 14(26):2683-2690. PubMed ID: 29927336
[TBL] [Abstract][Full Text] [Related]
9. Pseudoprogression: an indicator for cure in combined immunotherapy?
Zhao L; Yang Y; Li W; Li T; Han L; Lin H; Gao Q
Immunotherapy; 2019 Sep; 11(13):1087-1093. PubMed ID: 31361166
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.
Mehrvarz Sarshekeh A; Overman MJ; Kopetz S
Future Oncol; 2018 Aug; 14(18):1869-1874. PubMed ID: 29473436
[TBL] [Abstract][Full Text] [Related]
11. Combination of High Dose Hypofractionated Radiotherapy with Anti-PD1 Single Dose Immunotherapy Leads to a Th1 Immune Activation Resulting in a Complete Clinical Response in a Melanoma Patient.
Milhem C; Moralès O; Ingelaere C; Pasquier D; Mordon S; Mortier L; Mirabel X; Delhem N
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32942768
[TBL] [Abstract][Full Text] [Related]
12. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S
Front Immunol; 2018; 9():1769. PubMed ID: 30108590
[TBL] [Abstract][Full Text] [Related]
13. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature.
Messer A; Drozd B; Glitza IC; Lu H; Patel AB
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941716
[TBL] [Abstract][Full Text] [Related]
14. Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma.
Oliveira LJC; Gongora ABL; Barbosa FG; Dos Anjos CH; Munhoz RR
J Immunother Cancer; 2018 Nov; 6(1):130. PubMed ID: 30482243
[TBL] [Abstract][Full Text] [Related]
15. Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review.
Di Stefano RF; Buttigliero C; De Luca E; Reale ML; Pisano C; Leone G; Zichi C; Massa F; Manfredi M; Vignani F; Bollito E; Porpiglia F; Di Maio M; Tucci M
Clin Genitourin Cancer; 2018 Dec; 16(6):e1087-e1090. PubMed ID: 30122516
[No Abstract] [Full Text] [Related]
16. Exceptional response to chemotherapy followed by concurrent radiotherapy and immunotherapy in a male with primary retroperitoneal serous Adenocarcinoma: a case report and literature review.
Chae YK; Saleem N; Roh Y; Bilal H; Viveiros P; Sukhadia B; Lin X; Sheikh MM; Park LC
BMC Cancer; 2019 Jul; 19(1):748. PubMed ID: 31362708
[TBL] [Abstract][Full Text] [Related]
17. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
[No Abstract] [Full Text] [Related]
18. A case of gastric cancer with delayed onset of tumor reduction effect by nivolumab therapy.
Satoyoshi R; Muto O; Masuda A; Kotanagi K; Kichiraku T; Kudoh K; Sawada T; Miyazawa H; Kotanagi H
Clin J Gastroenterol; 2019 Feb; 12(1):15-19. PubMed ID: 30206777
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Australian patients receiving non-funded anti-PD-1 immune checkpoint inhibitors for non-melanoma cancers.
Tiu C; Wong A; Herschtal A; Mileshkin L
Asia Pac J Clin Oncol; 2018 Aug; 14(4):337-342. PubMed ID: 29498208
[TBL] [Abstract][Full Text] [Related]
20. Prolonged Disease Control with Nivolumab in Metastatic Lung Adenocarcinoma During Immunotherapy Era.
Sari M; Saip P
J Coll Physicians Surg Pak; 2018 Nov; 28(11):891-892. PubMed ID: 30369388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
